^
    Apply
    A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer (NCT05044988)
    Phase 2
    Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/15/2021
    Initiation :
    09/30/2021
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    HER-2
    |
    HR positive • HER-2 negative
    |
    HS-10342